This post is a case study in how shills operate: lead with sarcasm, bury substance under loaded language, and hope retail investors forget how much they’ve already learned.
Let’s deal in facts.
“All the Cognate cash went to the CEO-CFO’s private company.”
Wrong. NWBO didn’t just pay a vendor, they acquired Cognate through Toucan, an investment vehicle run by Linda Powers. This wasn’t some backroom deal. It was publicly disclosed and voted on, with full SEC documentation. NWBO secured access to its own GMP infrastructure for a personalized, autologous cell therapy at a time when no one else had that kind of control.
Retail shareholders weren’t looted, they were protected from long-term dependence on third-party CDMOs. Cognate manufactured and preserved hundreds of DCVax-L doses under strict GMP conditions, which were later used to dose crossover patients, some as many as seven years after surgery. That infrastructure wasn’t speculative. It worked.
“She even personally received back NWBO shares.”
Yes, and in return, she gave up tens of millions in secured debt and obligations. She didn’t cash out, she recapitalized the company in equity, aligning herself with long-term shareholders. If she thought NWBO was going nowhere, she would have demanded cash.
“Cognate wasn’t bought for $800M because of their DC capability.”
Actually, that’s exactly why Charles River bought them.
Cognate had specialized in cell therapy long before it was mainstream. It built real-world capabilities around autologous workflows, regulatory interfaces, and early-phase GMP supply. Charles River confirmed publicly that the acquisition was designed to expand their footprint in cell and gene therapy.
They didn’t buy branding. They bought infrastructure and know-how. DC was part of the core value.
“Advent will likely go down the same way. Just look at their website.”
This argument collapses immediately.
Advent’s website isn’t built for biotech tourists, it’s a working GMP CDMO, licensed by the UK MHRA to manufacture ATMPs, including DCVax-L. Their capabilities aren’t measured by website aesthetics but by regulatory standing, validated cleanrooms, and production history.
Advent operates the Sawston facility, which has already been approved to manufacture DCVax-L under the UK’s Specials framework, using a live MHRA license. That license wasn’t handed out for style points. It was earned through inspection, compliance, and real execution.
And that execution is ongoing.
“Look at their immune cell list. Dendritic cells are just one of many.”
Correct, and that’s what you’d want from a serious ATMP manufacturer. They’re not a frozen shell company. They’re a living, breathing operation with multi-line capability. That includes dendritic cells. That includes T cells. That includes the precise cell types required for immune therapies under development today.
A platform manufacturer is supposed to have that range. That’s a feature, not a flaw.
Here’s what doesn’t get said:
– Cognate was acquired by NWBO because they needed reliable GMP supply during and after the Phase 3 trial.
– Toucan gave NWBO control.
– Advent expanded that into the UK with a working facility and an MHRA license.
– DCVax-L is already being manufactured and shipped under Specials, legally and operationally.
– The foundation is real, the infrastructure is built, and the regulatory path is active.
When critics ignore filings, licenses, ownership structures, crossover success, GMP validations, and Specials access, it’s not analysis. It’s deflection.
Shill behavior isn’t about disagreement. It’s about deliberately steering the conversation away from facts and toward emotional innuendo.
That’s what this post tried to do.
It didn’t work.
Bullish
AI
